Family Medicine, Diabetology · Utica, NY
NPI
1972911352
Since 2014
Specialty
Family Medicine, Diabetology
Code 207QD0401X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
111 Hospital Dr
Utica, NY, 13502
Phone (315) 917-9966
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
531 services
Medicare patients, 2024
177
Average age 71
Drug cost, 2024
$1.2M
2,448 prescriptions
Company payments, 2025
$12K
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nay Linn Aung was code 99231 (hospital e&m - subsequent), 165 times for 43 patients. In total Nay Linn Aung billed 531 services in 20 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99231 Hospital E&M - Subsequent | Facility | 165 | 43 | $40.22 | $6,637 |
| 99451 E&M - Miscellaneous | Facility | 152 | 58 | $28.32 | $4,304 |
| 99214 Office E&M - Established | Office | 72 | 43 | $65.23 | $4,696 |
| 99213 Office E&M - Established | Office | 50 | 40 | $36.50 | $1,825 |
| 99221 Hospital E&M - Initial | Facility | 17 | 16 | $67.14 | $1,141 |
| 95251 Test - Miscellaneous | Office | 16 | 11 | $23.00 | $368 |
By year: 2022 $13K for 219 services; 2023 $18K for 392 services; 2024 $22K for 531 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nay Linn Aung prescribed most often to Medicare patients was Ozempic (Semaglutide), with 532 prescriptions and refills. In total Nay Linn Aung wrote 2,448 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 532 | 603 | 108 | $531K |
| Jardiance Empagliflozin | 355 | 411 | 66 | $234K |
| Glipizide Generic | 179 | 242 | 31 | $856 |
| Metformin Hcl Er Metformin Hcl | 157 | 214 | 30 | $1,084 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 157 | 287 | 39 | $18K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 118 | 140 | 23 | $77K |
| Metformin Hcl Generic | 116 | 230 | 34 | $717 |
| Repaglinide Generic | 73 | 83 | 12 | $1,508 |
| Trulicity Dulaglutide | 66 | 73 | 14 | $64K |
| Januvia Sitagliptin Phosphate | 55 | 67 | 11 | $37K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 52 | 92 | 15 | $14K |
| Mounjaro Tirzepatide | 46 | 46 | 11 | $46K |
| Novolog Flexpen Insulin Aspart | 41 | 60 | 14 | $5,626 |
| Tradjenta Linagliptin | 38 | 48 | Under 11 | $23K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 32 | 41 | 11 | $6,482 |
Brand drugs: 1,720 claims; generic drugs: 590 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nay Linn Aung $12K ($12K in general payments such as food, travel and fees) from 4 companies. The largest payer was Novo Nordisk Inc with $12K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.